• On 5 August 2026, Bausch + Lomb Corporation reshaped its board by appointing four new directors to replace four resigning members, including experienced leaders from healthcare, asset management and private investment firms.
• This board overhaul comes as the company contends with rising capital intensity, lower free cash flow margins and a 1.5% return on capital, highlighting governance as a key lever for tackling operational challenges.
• Next, we’ll examine how this boardroom refresh, amid ongoing operational headwinds, may influence Bausch + Lomb’s existing investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe its broad eye‑care platform can turn steady revenue into sustainable profitability despite capital intensity and thin returns. The recent board reshuffle adds governance experience, but it does not obviously change the near term focus on improving free cash flow and lifting a 1.5% return on capital, or the key risk that heavy reinvestment continues to weigh on margins.

The most relevant recent announcement here is the raised full year 2026 revenue guidance to US$5.44–5.54 billion, alongside narrowing losses in Q1 and Q2. That guidance underpins the current catalyst of earnings improvement, while the new directors may influence how rigorously management balances growth investments against the company’s already pressured free cash flow and capital returns.

Yet, beneath the higher sales guidance, investors should be aware of how rising capital intensity and weak free cash flow could still...

Bausch + Lomb's narrative projects $6.3 billion revenue and $247.8 million earnings by 2029. This requires 5.9% yearly revenue growth and a $418.8 million earnings increase from -$171.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $18.62 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts expected revenue near US$6.4 billion and earnings of about US$490 million by 2029, which is far rosier than consensus and could look different once this board overhaul and its impact on Vision 27 cost efforts are fully reflected in refreshed views.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth just $18.62!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.